IRIS
NUVOLONE, MARIO ULISSE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.718
AS - Asia 2.808
EU - Europa 1.819
SA - Sud America 434
Continente sconosciuto - Info sul continente non disponibili 204
AF - Africa 176
OC - Oceania 6
Totale 9.165
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.619
CN - Cina 1.033
SG - Singapore 693
IE - Irlanda 510
HK - Hong Kong 372
VN - Vietnam 343
BR - Brasile 325
RU - Federazione Russa 271
DE - Germania 210
IT - Italia 176
FI - Finlandia 155
FR - Francia 143
ZA - Sudafrica 141
GB - Regno Unito 89
BD - Bangladesh 73
IN - India 70
UA - Ucraina 60
CA - Canada 50
AR - Argentina 42
MX - Messico 31
ES - Italia 30
IQ - Iraq 29
SE - Svezia 29
PL - Polonia 26
JP - Giappone 24
TR - Turchia 23
NL - Olanda 19
AT - Austria 17
CO - Colombia 17
PK - Pakistan 17
BE - Belgio 16
SA - Arabia Saudita 16
ID - Indonesia 14
EC - Ecuador 13
LT - Lituania 11
VE - Venezuela 11
JO - Giordania 9
LB - Libano 9
PH - Filippine 9
UZ - Uzbekistan 9
MA - Marocco 8
AE - Emirati Arabi Uniti 7
AL - Albania 7
UY - Uruguay 7
CH - Svizzera 6
CL - Cile 6
EG - Egitto 6
JM - Giamaica 6
MY - Malesia 6
PT - Portogallo 6
PY - Paraguay 6
TN - Tunisia 6
AU - Australia 5
AZ - Azerbaigian 5
BG - Bulgaria 5
KE - Kenya 5
TH - Thailandia 5
DK - Danimarca 4
IR - Iran 4
KR - Corea 4
NO - Norvegia 4
AM - Armenia 3
BH - Bahrain 3
BN - Brunei Darussalam 3
BO - Bolivia 3
CZ - Repubblica Ceca 3
HN - Honduras 3
HR - Croazia 3
IL - Israele 3
PE - Perù 3
CY - Cipro 2
GA - Gabon 2
GE - Georgia 2
GR - Grecia 2
KZ - Kazakistan 2
LU - Lussemburgo 2
LV - Lettonia 2
MK - Macedonia 2
MN - Mongolia 2
MU - Mauritius 2
NG - Nigeria 2
NP - Nepal 2
QA - Qatar 2
RO - Romania 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BY - Bielorussia 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
ET - Etiopia 1
EU - Europa 1
GP - Guadalupe 1
GT - Guatemala 1
IS - Islanda 1
KG - Kirghizistan 1
Totale 8.945
Salva come PNG Salva come JPEG
Città #
Dublin 510
San Jose 473
Singapore 381
Hong Kong 361
Ashburn 356
Chandler 349
Dallas 282
Beijing 246
Nanjing 158
Council Bluffs 153
Boardman 138
Johannesburg 128
Los Angeles 117
Ho Chi Minh City 105
Lauterbourg 101
Helsinki 96
Jacksonville 94
Hanoi 93
New York 76
Princeton 73
Lawrence 68
Munich 58
Wilmington 57
Medford 53
Nanchang 53
Ann Arbor 52
Buffalo 50
Redondo Beach 49
Shanghai 48
Shenyang 42
São Paulo 42
Orem 40
Jiaxing 38
Moscow 36
Pavia 36
Santa Clara 36
Hebei 35
Changsha 34
Hangzhou 31
Milan 29
Tianjin 24
Tokyo 23
Warsaw 23
Frankfurt am Main 22
Atlanta 21
Denver 21
Da Nang 19
London 19
Montreal 18
Nuremberg 18
The Dalles 18
Columbus 17
Haiphong 17
San Francisco 17
Norwalk 16
Poplar 16
Turku 16
Woodbridge 16
Brussels 15
Mexico City 15
Redwood City 15
Seattle 15
Toronto 15
Chennai 14
Falkenstein 14
Brooklyn 13
Chicago 13
Phoenix 13
Piscataway 13
Ankara 11
Stockholm 11
Baghdad 10
Houston 10
Rome 10
Amman 9
Amsterdam 9
Belo Horizonte 9
Fairfield 9
Hải Dương 9
Rio de Janeiro 9
Riyadh 9
Washington 9
Biên Hòa 8
Brasília 8
Charlotte 8
Beirut 7
City of London 7
Curitiba 7
Guangzhou 7
Hyderabad 7
Manchester 7
Vienna 7
Boston 6
Jeddah 6
Manaus 6
Medellín 6
Montevideo 6
Paris 6
Tamm 6
Tashkent 6
Totale 5.918
Salva come PNG Salva come JPEG
Nome #
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 217
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 154
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 138
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 128
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 125
Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis 125
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 123
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 122
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 122
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 120
Bone marrow amyloidosis. 119
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 117
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 117
Identification of genes for normalization of RT-qPCR gene expression data: A review of published literature 116
Prognostication of survival and progression to dialysis in AA amyloidosis 116
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 114
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 112
Bone marrow microenvironment in light-chain amyloidosis: In vitro expansion and characterization of mesenchymal stromal cells 112
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 111
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 110
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 108
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 107
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 105
Altered monoaminergic systems and depressive-like behavior in congenic prion protein knock-out mice 104
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 103
Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis:insights into the timing of proteolysis 103
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 102
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis 101
Analysis of cyclin D1 mRNA expression levels in plasma cell dyscrasias: A systematic review of published literature 99
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 98
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 95
Amyloid diseases at the molecular level: general overview and focus on AL amyloidosis. 93
Regulated expression of amyloidogenic immunoglobulin light chains in mice 92
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 92
A case of monoclonal gammopathy of renal significance 92
Helical superstructures between amyloid and collagen in cardiac fibrils from a patient with AL amyloidosis 91
Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients 89
A nationwide prospective registry of bortezomib-based therapy in light chain (AL) amyloidosis 89
Development and Validation of Staging Systems for AA Amyloidosis 86
Cystatin F is a biomarker of prion pathogenesis in mice 85
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 85
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 84
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 82
Prion protein and Ab-related synaptic toxicity impairment 80
Cells and prions: A license to replicate 80
Treating Protein Misfolding Diseases: Therapeutic Successes Against Systemic Amyloidoses 80
Extended characterization of the novel co-isogenic C57BL/6J Prnp−/− mouse line 79
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis 79
The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6 78
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 78
Genome-wide transcriptomics identifies an early preclinical signature of prion infection 77
Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis 77
The Cryo-EM STRUCTURE of Renal Amyloid Fibril Suggests Structurally Homogeneous Multiorgan Aggregation in AL Amyloidosis 76
Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter 76
Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach 76
A neuroprotective role for microglia in prion diseases 76
Prion pathogenesis in the absence of NLRP3/ASC inflammasomes 76
Efficient amyloid A clearance in the absence of immunoglobulins and complement factors 76
The complex PrPc-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease 76
Expanding the spectrum of systemic amyloid diseases: a new hint from the kidney 73
Efficient generation of multipotent mesenchymal stem cells from umbilical cord blood in stroma-free liquid culture 73
A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis 73
Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy 72
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development 71
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis 71
Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study 70
Structure-based drug design identifies polythiophenes as antiprion compounds 70
A Strategy for the Selection of RT-qPCR Reference Genes Based on Publicly Available Transcriptomic Datasets 68
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis 68
Nanobodies counteract the toxicity of an amyloidogenic light chain by stabilizing a partially open dimeric conformation 67
Prion pathogenesis is unaltered in a mouse strain with a permeable blood-brain barrier 67
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival 66
Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis 66
Brain aging is faithfully modelled in organotypic brain slices and accelerated by prions 66
Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis 65
Prion diseases disrupt glutamate/glutamine metabolism in skeletal muscle 64
The Role of the NADPH Oxidase NOX2 in Prion Pathogenesis 63
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 62
The workings of the amyloid diseases. 61
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside 61
Strictly co-isogenic C57BL/6J-Prnp-/- mice: A rigorous resource for prion science 60
Prion pathogenesis is unaltered in the absence of SIRPα-mediated "don't-eat-me" signaling 60
Improved outcomes for kidney transplantation in AL amyloidosis: impact on practice 59
Analysis of co-isogenic prion protein deficient mice reveals behavioral deficits, learning impairment, and enhanced hippocampal excitability 58
Systemic amyloidosis: novel therapies and role of biomarkers 57
The Priority position paper: Protecting Europe's food chain from prions 57
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 56
SMaRT M-Seq: an optimized step-by-step protocol for M protein sequencing in monoclonal gammopathies 56
SIRPα polymorphisms, but not the prion protein, control phagocytosis of apoptotic cells 56
The ASC inflammasome adapter governs SAA-derived protein aggregation in inflammatory amyloidosis 54
Author Correction: The dengue-specific immune response and antibody identification with machine learning 53
The immunobiology of prion diseases 52
Management of the elderly patient with AL amyloidosis 52
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients 52
The Interaction of the Tumor Suppressor FAM46C with p62 and FNDC3 Proteins Integrates Protein and Secretory Homeostasis 51
Glial activation in prion diseases is selectively triggered by neuronal PrPSc 50
Tau Exon 10 Inclusion by PrPC through Downregulating GSK3β Activity 49
Lymphocyte activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression 48
TENT5C/FAM46C modulation in vivo reveals a trade-off between antibody secretion and tumor growth in multiple myeloma 47
Redirecting proteoxicity 47
Totale 8.434
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.996
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.996
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022277 0 5 3 0 8 9 6 26 20 5 40 155
2022/20231.175 119 89 20 66 92 104 25 51 563 6 29 11
2023/2024471 59 103 25 28 46 102 16 26 6 18 22 20
2024/20251.541 28 110 12 37 17 119 94 97 401 69 187 370
2025/20264.350 283 271 371 507 606 157 795 271 472 284 134 199
2026/2027346 200 146 0 0 0 0 0 0 0 0 0 0
Totale 9.165